Literature DB >> 19828598

Brain multiple sclerosis-like lesions in a patient with Muckle-Wells syndrome.

Sandrine Compeyrot-Lacassagne, Tu-Anh Tran, Séverine Guillaume-Czitrom, Isabelle Marie, Isabelle Koné-Paut.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19828598     DOI： 10.1093/rheumatology/kep321

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  15 in total

1.  NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy.

Authors:  Hiroshi Nakanishi; Yoshiyuki Kawashima; Kiyoto Kurima; Jae Jin Chae; Astin M Ross; Gineth Pinto-Patarroyo; Seema K Patel; Julie A Muskett; Jessica S Ratay; Parna Chattaraj; Yong Hwan Park; Sriharsha Grevich; Carmen C Brewer; Michael Hoa; H Jeffrey Kim; John A Butman; Lori Broderick; Hal M Hoffman; Ivona Aksentijevich; Daniel L Kastner; Raphaela Goldbach-Mansky; Andrew J Griffith
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-28       Impact factor: 11.205

Review 2.  Inflammasomes and autoimmunity.

Authors:  Patrick J Shaw; Michael F McDermott; Thirumala-Devi Kanneganti
Journal:  Trends Mol Med       Date:  2010-12-14       Impact factor: 11.951

3.  Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis.

Authors:  Chunqing Guo; Jacob W Fulp; Yuqi Jiang; Xia Li; Jeremy E Chojnacki; Jingde Wu; Xiang-Yang Wang; Shijun Zhang
Journal:  ACS Chem Neurosci       Date:  2017-07-13       Impact factor: 4.418

4.  Effect of sphingosine kinase modulators on interleukin-1β release, sphingosine 1-phosphate receptor 1 expression and experimental autoimmune encephalomyelitis.

Authors:  Mark Barbour; Melissa McNaughton; Stephanie D Boomkamp; Neil MacRitchie; Hui-Rong Jiang; Nigel J Pyne; Susan Pyne
Journal:  Br J Pharmacol       Date:  2016-12-20       Impact factor: 8.739

5.  The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18.

Authors:  Sushmita Jha; Siddharth Y Srivastava; W June Brickey; Heather Iocca; Arrel Toews; James P Morrison; Vivian S Chen; Denis Gris; Glenn K Matsushima; Jenny P-Y Ting
Journal:  J Neurosci       Date:  2010-11-24       Impact factor: 6.167

Review 6.  Autoinflammatory diseases in childhood, part 1: monogenic syndromes.

Authors:  María Navallas; Emilio J Inarejos Clemente; Estíbaliz Iglesias; Mónica Rebollo-Polo; Faizah Mohd Zaki; Oscar M Navarro
Journal:  Pediatr Radiol       Date:  2020-02-17

7.  Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations.

Authors:  Elisabeth Schuh; Peter Lohse; Birgit Ertl-Wagner; Matthias Witt; Markus Krumbholz; Marion Frankenberger; Lisa-Ann Gerdes; Reinhard Hohlfeld; Tania Kümpfel
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-05-14

Review 8.  Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration.

Authors:  Roman Sankowski; Simone Mader; Sergio Iván Valdés-Ferrer
Journal:  Front Cell Neurosci       Date:  2015-02-02       Impact factor: 5.505

9.  Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis.

Authors:  Brienne A McKenzie; Manmeet K Mamik; Leina B Saito; Roobina Boghozian; Maria Chiara Monaco; Eugene O Major; Jian-Qiang Lu; William G Branton; Christopher Power
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-12       Impact factor: 11.205

10.  NLRP3 Inflammasome and MS/EAE.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Autoimmune Dis       Date:  2013-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.